Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

Classen, S.; Kopp, Ryan; Possinger, K.; Weidenhagen, R.; Eiermann, W.; Wilmanns, W.

doi:10.1159/000059706

Cited by 27 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic breast cancer (MBC) patients appear to have a higher percentage of positive serum HER2 ECD than primary breast cancer (PBC) (43% v.s. 18%) (Figure 1) [32, 37, 38]. Serum HER2 ECD prevalence rate from our analysis is in general consistent with previous report in 2003 [42].…”

Section: Prevalence Of Her2 Ecd In Breast Cancerssupporting

confidence: 91%

See 1 more Smart Citation

Challenges in the clinical utility of the serum test for HER2 ECD

Lam¹,

McAndrew²,

Yee³

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Section: Prevalence Of Her2 Ecd In Breast Cancerssupporting

confidence: 91%

“…Breast cancer patients with elevated HER2 ECD serum levels had a limited response to hormone or chemotherapy [13, 38, 40, 54] and a reduced response rate to tamoxifen (an antiestrogen) or letrozole (an aromatase inhibitor) [57]. …”

Section: Clinical Utility Of Serum Her2 Ecd Measurementmentioning

confidence: 99%

Challenges in the clinical utility of the serum test for HER2 ECD

Lam¹,

McAndrew²,

Yee³

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…Circulating HER-2/neu receptor protein levels have successfully predicted the presence and progression of HER-2/neu-positive breast cancer. In 22 published studies on 4,088 patients, 16 (73%) studies involving 3,458 (85%) of the patients reported a significant correlation between serum HER-2/neu protein levels and either disease recurrence, metastasis, or shortened survival [125,[150][151][152][153][154][155][156][157][158][159][160][161][162][163][164]. Two studies involving 379 patients reported no significant association between serum level and prognosis [165,166].…”

Section: Serum Her-2/neu Antigen Level As a Tumor Markermentioning

confidence: 99%

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

et al. 2003

View full text Add to dashboard Cite

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages and disadvantages of Southern blotting, polymerase chain reaction amplification, andThe Oncologist 2003;8:307-325 www.TheOncologist.comCorrespondence: Jeffrey S. Ross, M.D., Albany Medical College, Department of Pathology, Mail Code 81, 47 New Scotland Avenue, Albany, New York 12208, USA. Telephone: 518-262-5461; Fax: 518-262-8092; e-mail: rossj@mail.amc.edu Received February 5, 2003; accepted for publication April 28, 2003. ©AlphaMed Press 1083-7159/2003 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Define the historical background and biological basis of the discovery of the HER-2/neu gene and its first use as a prognostic factor in breast cancer.2. Recall the uses of HER-2/neu testing prior to the approval of trastuzumab including the impact on anthracycline adjuvant and first-line chemotherapy responses.3. Explain the basic principles of all the HER-2/neu tests in clinical practice: IHC, FISH, Southern blot, PCR, tissue ELISA, and serum ELISA.4. Contrast the pros and cons and uses and limitations of the IHC versus the FISH approach to HER-2/neu testing.5. Critique the most recent data comparing IHC with FISH for the prediction of response to single-agent trastuzumab and trastuzumab in combination with standard chemotherapy for advanced metastatic breast cancer.6. Describe the HER-2/neu expression patterns in all types of breast conditions, including in situ carcinoma, lobular versus ductal carcinoma, Paget's disease, male breast cancer, breast sarcomas, and benign breast disorders.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Ross, Fletcher, Linette et al. 308 HER-2/NEU GENE (C-ERBB-2)The human epidermal growth factor receptor 2 (HER-2)/neu (c-erbB-2) gene is localized to chromosome 17q and encodes a transmembrane tyrosine kinase receptor protein that is a member of the epidermal growth factor receptor (EGFR) or HER family ( Fig. 1) [1]. This family of receptors is involved in cell-to-cell and cell-to-stroma communication primarily through a process known as signal transduction, in which external growth factors, or ligands, affect the transcription of various genes by phosphorylating or dephosphorylating a series of transmembrane proteins and intracellular signaling intermediates, many of which possess enzymatic activity. Signal propagation occurs as the enzymatic activity of one protein turns on the enzymat...

show abstract

“…By definition of a lack of receptors for ER, PR and Her2/ neu, patients with triple-negative tumors are excluded from adjuvant hormonal therapy or trastuzumamb. 34 Extensive subtyping through molecular profiling may help identify patients with a potential to respond to combinations of specific regimens. Whether or not, alternative types of chemotherapy associated with a variety of biologic modifiers or targeted antibodies will prove to be superior can only be clarified by accurately designed prospective studies.…”

Section: Discussionmentioning

confidence: 99%

Breast-Cancer Subtyping in Clinical Practice: Clinicopathologic Features and Outcomes

MastorakiAikaterini¹,

KazaniAikaterini²,

MastorakiSotiria³

et al. 2014

Journal of Gynecologic Surgery

View full text Add to dashboard Cite

Background:The main molecular markers associated with breast cancer that classify patients into subtypes are estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2/neu) proteins. Based on ER, PR and HER2/neu analysis, tumors can be divided into the categories of basal-like, luminal, or HER2/neu positive. Objectives: The aim of this survey was to elucidate the efficacy of the prognostic significance of this classification scheme and to compare the clinicopathologic features and survival in the abovementioned subtypes defined by immunohistochemistry (IHC) in association with a variety of clinical and surgical parameters. Materials and Methods: For this prospective study, 163 women, ages 28-87, were registered consecutively. In each case in the database ER, PR, and HER2/neu levels were obtained through standard clinical testing, using IHC for ER and PR and the HercepTest for HER2/neu. Results: The statistical analysis of this sample showed that patients who were characterized as ER(-) and PR(-) had the worst survival, compared to HR( + ) women ( p < 0.001). In addition, there seemed to be strong relationship between a positive HER2/neu immunohistochemical profile and long-term survival ( p < 0.001). Furthermore, a higher proportion of triplenegative patients experienced distant recurrence and their mean time to disease progression was significantly shorter ( p < 0.001). Thus triple-negative classification was an independent predictor of disease aggressiveness or metastatic potential. Conclusions: Patients with triple-negative breast cancer have an increased likelihood of distant recurrence and death, compared to women with other types of breast cancer. Furthermore, the patterns of relapse in the two subgroups are completely different. ( J GYNECOL SURG 30:260)

show abstract

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy

Cited by 27 publications

References 26 publications

Challenges in the clinical utility of the serum test for HER2 ECD

Challenges in the clinical utility of the serum test for HER2 ECD

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

Breast-Cancer Subtyping in Clinical Practice: Clinicopathologic Features and Outcomes

Contact Info

Product

Resources

About